amifostine anhydrous has been researched along with Hypotension in 17 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The lack of improved duration of response or impact on survival may be the result of the limited improvement of efficacy with the higher dosage of cisplatin in conjunction with WR-2721, or the limited number of patients accrued to this study." | 2.71 | Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). ( Borden, E; Ewell, M; Glick, J; Glover, D; Ibrahim, J; Karp, D; Kirkwood, J; Stewart, J, 2003) |
| " This is the first report focusing on amifostine related adverse effects leading to discontinuation of amifostine treatment." | 2.71 | Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. ( Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004) |
| "Hypotension was the most important adverse event of AMI infusion." | 2.70 | A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. ( Jantunen, E; Kuittinen, T; Nousiainen, T, 2002) |
| " We conclude that WR-2721 is a potentially toxic compound that produces no amelioration of cyclophosphamide toxicity in the doses used." | 2.65 | Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. ( Ayoob, MJ; Dritschilo, A; Smith, FP; Woolley, PV, 1983) |
| " The dosing and administration guidelines are reviewed." | 2.39 | Amifostine (Ethyol): dosing, administration and patient management guidelines. ( Bukowski, RM, 1996) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| "Emesis was significantly influenced by infusion time; the long schedule caused a 57% incidence whereas the short schedule caused only a 28% incidence." | 1.27 | Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. ( Glick, J; Glover, DJ; Hurwitz, S; Kligerman, MM; Norfleet, AL; Turrisi, AT; Weiler, C; Yuhas, JM, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soref, CM | 1 |
| Hacker, TA | 1 |
| Fahl, WE | 1 |
| Jantunen, E | 1 |
| Kuittinen, T | 1 |
| Nousiainen, T | 1 |
| Glover, D | 1 |
| Ibrahim, J | 1 |
| Kirkwood, J | 1 |
| Glick, J | 2 |
| Karp, D | 1 |
| Stewart, J | 1 |
| Ewell, M | 1 |
| Borden, E | 1 |
| Rades, D | 1 |
| Fehlauer, F | 1 |
| Bajrovic, A | 1 |
| Mahlmann, B | 1 |
| Richter, E | 1 |
| Alberti, W | 1 |
| Fisher, MJ | 1 |
| Lange, BJ | 1 |
| Needle, MN | 1 |
| Janss, AJ | 1 |
| Shu, HK | 1 |
| Adamson, PC | 1 |
| Phillips, PC | 1 |
| Woolley, PV | 1 |
| Ayoob, MJ | 1 |
| Smith, FP | 1 |
| Dritschilo, A | 1 |
| Ryan, SV | 1 |
| Carrithers, SL | 1 |
| Parkinson, SJ | 1 |
| Skurk, C | 1 |
| Nuss, C | 1 |
| Pooler, PM | 1 |
| Owen, CS | 1 |
| Lefer, AM | 1 |
| Waldman, SA | 1 |
| Bukowski, RM | 1 |
| Tannehill, SP | 1 |
| Mehta, MP | 1 |
| Larson, M | 1 |
| Storer, B | 1 |
| Pellet, J | 1 |
| Kinsella, TJ | 1 |
| Schiller, JH | 1 |
| Ramnath, N | 1 |
| LoRusso, P | 1 |
| Simon, M | 1 |
| Martino, S | 1 |
| Raza, A | 1 |
| Qawi, H | 1 |
| Lisak, L | 1 |
| Andric, T | 1 |
| Dar, S | 1 |
| Andrews, C | 1 |
| Venugopal, P | 1 |
| Gezer, S | 1 |
| Gregory, S | 1 |
| Loew, J | 1 |
| Robin, E | 1 |
| Rifkin, S | 1 |
| Hsu, WT | 1 |
| Huang, RW | 1 |
| Shaw, PJ | 1 |
| Bleakley, M | 1 |
| Chauncey, TR | 1 |
| Gooley, TA | 1 |
| Lloid, ME | 1 |
| Schubert, MM | 1 |
| Lilleby, K | 1 |
| Holmberg, L | 1 |
| Bensinger, WI | 1 |
| Godette, KD | 1 |
| Thomas, CR | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Buzaid, AC | 1 |
| Murren, J | 1 |
| Durivage, HJ | 1 |
| Turrisi, AT | 1 |
| Glover, DJ | 1 |
| Hurwitz, S | 1 |
| Norfleet, AL | 1 |
| Weiler, C | 1 |
| Yuhas, JM | 1 |
| Kligerman, MM | 1 |
1 review available for amifostine anhydrous and Hypotension
| Article | Year |
|---|---|
Amifostine (Ethyol): dosing, administration and patient management guidelines.
Topics: Amifostine; Antineoplastic Agents; Drug Administration Schedule; Humans; Hypotension | 1996 |
8 trials available for amifostine anhydrous and Hypotension
| Article | Year |
|---|---|
A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Feasibility Studies; Fe | 2002 |
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Body Weight | 2003 |
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Drug | 2004 |
Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
Topics: Adult; Aged; Amifostine; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; | 1983 |
Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 1997 |
Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 1997 |
High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug | 1991 |
8 other studies available for amifostine anhydrous and Hypotension
| Article | Year |
|---|---|
A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
Topics: Administration, Oral; Amifostine; Animals; Diamines; Drug Evaluation, Preclinical; Female; Ferrets; | 2012 |
Hypotensive mechanisms of amifostine.
Topics: Adrenergic Agents; Amifostine; Animals; Aorta, Thoracic; Arginine; Blood Pressure; Calcium; Cyclic A | 1996 |
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anorexia; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Systemic inflammatory response syndrome associated with amifostine.
Topics: Amifostine; Antineoplastic Agents; Brain Stem Neoplasms; Child, Preschool; Drug Eruptions; Edema; Er | 2000 |
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2000 |
Clarification on the potential of subcutaneous ethyol as a radioprotective agent.
Topics: Amifostine; Humans; Hypotension; Injections, Subcutaneous; Radiation-Protective Agents | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid].
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Hypotension; Infusi | 1986 |